ALLO Allogene Therapeutics receives FDA regenerative Medicine advanced therapy (rmat) designation for cemacabtagene ansegedleucel (cema-cel)
ALLO Allogene Therapeutics receives FDA regenerative Medicine advanced therapy (rmat) designation for cemacabtagene ansegedleucel (cema-cel) as first-line consolidation therapy for large B-cell lymphoma
Story updates
12:31:30 PM UTC
SquawkNews
ALLO - Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Cemacabtagene Ansegedleucel (Cema-Cel) as First-Line Consolidation Therapy for Large B-Cell Lymphoma - Click For Release
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.